ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
A team of immunologists at Yale University has uncovered a crucial aspect of how aluminum compounds called adjuvants make some types of vaccines more effective. Their results could lead to improved vaccine formulations (Nature, DOI: 10.1038/nature06939). Named after the Latin word for aid, adjuvants (almost always aluminum hydroxide) aggregate into particles onto which vaccine antigens can adsorb. In doing so, adjuvants help vaccine antigens get the attention of immune cells before they are cleared from the body. But the specific molecular pathways that they activate have remained unknown. Now, Richard A. Flavell's group at Yale has found that aluminum hydroxide triggers a specific conglomerate of enzymes that ultimately turn on cytokines, proteins that help direct the immune system's response to pathogens. This result doesn't discount the importance of adjuvant aggregates or rule out adjuvant activation of other immune pathways, postdoctoral fellow and study coauthor Stephanie C. Eisenbarth says. "Aluminum hydroxide is probably a good adjuvant because it can do multiple things," she adds.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X